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Objectives: To analyse serogroup (Sg)- and finetype-specific invasive meningococcal disease burden 
(IMD) in Germany, 2002–2010, with emphasis on effects of vaccination with conjugate SgC vaccines 
targeting one-year old children since 2006, including individual-based catch-up to 17 years of age. 
Methods: Serogroup- and age-specific IMD incidence and trends were calculated using statutory 
surveillance data. The national reference laboratory performed genetic finetyping. Vaccination uptake 
data were obtained from school entry surveys and prescription monitoring. 
Results: In persons <25 years, SgB and SgC IMD incidence decreased significantly from 0.63 to 
0.32/100,000 and 0.26 to 0.10/100,000, respectively. The decline was significantly steeper for SgC 
than SgB in 1–5 year-olds, the primary vaccination target group, but not other ages. The slope of the 
SgC incidence curves was similar before and after vaccination implementation in all age groups; 
however, the decrease in incidence was steeper in states with higher vaccination uptake. Declining 
SgC incidence was associated with decreased SgC finetype diversity. An increase in SgY incidence 
was limited to adults. 
Conclusions: Results suggest effects of the German SgC vaccination strategy are limited, although 
interpretation is complicated by already low and decreasing incidence before vaccination. More 
effective use of vaccination resources might be achieved by rigorously targeting adolescents in 




While the overall incidence of invasive meningococcal disease (IMD), caused by Neisseria 
meningitidis, is relatively low in Europe (0.1–3.4 cases/100,000 inhabitants), case-fatality remains high 
at 7–9%. 
1 and 2
 Compared to other European countries, incidence in Germany (81.8 million inhabitants) 
is low. 
1 and 3
 Surveillance is based on statutory notification according to the German Protection Against 
Infection Act (IfSG) since 2001, with linkage to typing performed at the National Reference Laboratory 
for Meningococci (NRLM). 
In 2006, the German Standing Committee on Vaccination (STIKO) recommended routine 
meningococcal serogroup C (SgC) vaccination in the second year of life. Previously, SgC conjugate 
vaccines were recommended only for risk groups, except in the federal state of Saxony (4.1 million 
inhabitants), where SgC vaccination was recommended from 2 months of age in July 2003.
4
 STIKO 
recommended catch-up vaccination for all children and adolescents <18 years on an individual basis, 
5 and 6
 but a catch-up campaign was not undertaken. 




Materials and methods 
SgC vaccination coverage 
Vaccination coverage with conjugate SgC vaccines is ascertained routinely by local health authorities 
(LHA) from children at school entry and provided to the Robert Koch Institute (RKI) annually in 
aggregate form. Furthermore, the number of prescribed conjugate SgC vaccine doses from 2006 to 
2010 was analysed based on data purchased by RKI from Insight Health (http://www.insight-
health.de/), which collects data on all prescriptions for >99% of persons insured by the statutory health 
insurance (SHI) in Germany from pharmacy data processing centres. SHI covers ∼85% of the German 
population.
7
 We calculated the number of prescribed vaccine doses per 1000 one-year-old children, as 
these comprised the primary vaccination target group, for each state. We used the median value to 
categorize states as having high or low vaccination uptake. 
 
Surveillance 
According to IfSG, notification of IMD to LHA is required of physicians and laboratories. LHA verify 
notified cases according to the national case definition. Clinical criteria include at least one of fever, 
meningeal signs, skin lesions (maculopapular rash, petechiae, or ecchymoses), signs of increased 
intracranial pressure or circulatory collapse. Laboratory confirmation requires detection of N. 
meningitidis in blood, cerebrospinal fluid (CSF), skin biopsy of hemorrhagic infiltrates, or clinical 
specimens from a normally sterile site by culture, nucleic acid detection, microscopic detection of 
gram-negative diplococci or detection of capsular antigen (CSF only). Cases fulfilling clinical and either 
laboratory or epidemiological criteria (contact to laboratory-confirmed case) are considered confirmed, 
and transmitted from LHA to RKI via the state level in anonymized form together with data on 
vaccination status, clinical presentation (meningitis, sepsis, Waterhouse-Friderichsen Syndrome 
(WHF)), hospitalization, and outcome (survived/died). 
 
Laboratory methods 
NRLM routinely receives isolates or samples from IMD patients from peripheral laboratories and 
performs antigen sequence typing.
8
 A finetype is defined as the combination of serogroup, antigen 
sequence type of two variable regions (VR) of the outer membrane protein PorA and of one VR of 
FetA, resulting in the formula “Sg:PorA VR1,VR2:FetA VR”.
9
 Since 2004, all NRLM results are 
reported directly to LHA in addition to primary laboratories. NRLM cases were matched to notified 
cases using an automated algorithm requiring identical sex, month/year of birth, county and state of 
residence, ≤7 days between date of illness onset and date sample taken and a unique match. A 
manual search was performed for potential further matches fulfilling fewer criteria. These were verified 
at the level of the local health authority using personalized data not available at the national level. 
 
Data analysis 
IMD incidence was calculated using 2002–2010 notification data as of 4 July 2011 and population 
estimates from the Federal Statistical Office (http://www.destatis.de). Serogroup specific incidences 
were calculated assuming a similar serogroup distribution among cases with and without known 
serogroup. Proportions were compared using the Chi-squared test. Exact binomial confidence 
intervals were calculated for case-fatality estimates. Temporal trends were estimated using poisson 
and negative binomial regression analysis. Confidence bands (CI) were obtained using delta method. 




where s = total number of finetypes, nj = number of strains belonging to the j th finetype and N = total 
number of cases in the serogroup under consideration.
10
 Confidence intervals (CI) were calculated 
according to Grundmann et al.
11
 
Statistical analyses were performed using PASW SPSS 18 and STATA 11.0/IC. 
 
Results 
SgC vaccination coverage 
Based on data from 92% of children entering school in 13 of 16 federal states (4–6-year-old children 
presenting with vaccination records, n = 494,455), SgC vaccination coverage in 2010 was 69,8% 
(range: 52.8%–89.5%) (Table 1). In 2009, coverage was 55.9% (range in 13 states: 9.1%–79.5%).
12
 
These children would have been one year old in 2005–2007, making it likely that some were 
vaccinated at an older age. The number of annually prescribed SgC vaccine doses per 1000 one-
year-old children peaked in most states in 2007, the first full year after implementing the SgC 
vaccination recommendation in July 2006 (Table 1) with values > 1000/1000 reflecting recommended 
catch-up vaccination in older children. We categorized vaccine uptake as low in the 8 states with rates 
below the median of 1858/1000 and as high in the remaining states. The overall vaccination coverage 
at school entry in states classified as low was 61.1% and in states classified as high, 73.9%. 
 
Description of surveillance data base 
From 2002 to 2010, 5073 confirmed IMD cases were reported to RKI. Of these, 3600 (71.0%) were 
diagnosed by culture, 554 (10.9%) by PCR, 745 (14.7%) only by microscopy or antigen test, with no 
data for 114 (2.2%). A total of 3653 NRLM cases were matched to notified cases, 3505 of which had 
complete results of genetic finetyping available. The percentage of NRLM cases without a match 
decreased from 11.5% in 2002 to 2.4% in 2006 and was 2.8%–3.3% in 2007–2010. After matching to 
NRLM cases, the serogroup was available for 4488/5073 notified cases (88.5%, increasing from 
85.7% to 90.5% from 2002 to 2010). The notified and NRLM serogroup differed in 48 of the matched 
cases (1.3%) and was corrected according to NRLM results. 
Clinical presentation and case fatality 
The proportion of cases missing data on clinical presentation decreased from high levels shortly after 
IfSG-implementation (64.1% in 2002; 55.2% in 2003) to <10.5% in 2004–2010. Therefore, description 
of clinical manifestations was limited to data from 2004 to 2010 (n = 3353). Meningitis was reported in 
68.7% of cases and sepsis in 39.8% (both manifestations in 8.5%). WHF was reported in 30.0% of 
cases with sepsis (12% of all cases). Clinical presentation was similar in males and females, but 
adults ≥50 years presented with sepsis more often (51.5%) than younger persons, with the lowest 
frequency among 15–24 year olds (33.3%, p < 0.0001). Compared to cases with SgB (38.2%), cases 
with SgC (45.4%, p = 0.0007) and SgY (46.8%, p = 0.07), but not SgW135 (36.1%, p = 0.43), were 
more likely to present with sepsis. There was no difference in the percentage of cases presenting with 
WHF according to serogroup (p = 0.29). 
Data on vital status was available for 99.3% of cases reported during 2002–2010. Of 441 reported 
deaths, 298 (67.6%) occurred in persons <25 years. Case fatality (CF) was 8.8% (95%CI: 8.0–9.6%) 
overall, lowest in 5–14 year olds (4.2%) and highest in ≥50-year olds (15.8%). There was no difference 
in CF according to sex. CF was higher for SgC than SgB in all age groups (Table 2). A total of 15 and 
13 deaths, respectively, occurred among cases with SgY (CF: 8.4%, 95%CI: 4.6–14.0%) and SgW135 
(CF: 11.5%, 95%CI: 5.9–19.6%). 
 
IMD disease burden according to age, serogroup, and region 
The mean annual IMD incidence from 2002 to 2010 was 0.71 cases/100,000 inhabitants. Annual 
incidence was highest in 2003 at 0.94/100,000, decreasing to 0.47 in 2010. Mean IMD incidence was 
highest in infants (11.93/100,000), declining to lower levels in children aged 5–14 (1.00/100,000). A 
smaller peak was seen in 15–19-year olds (2.63/100,000), with a decrease to 0.82/100,000 in 20–24-
year olds and lowest incidences in adults >24 years (0.20/100,000). Mean IMD incidence was slightly 
higher in males than females (0.75/100,000 vs. 0.63/100,000, p < 0.0001) except among ≥50 year-
olds, in whom the incidence in women (0.23/100,000) was slightly higher than in men (0.18/100,000,  
p < 0.0001). 
As shown in online Table 1, SgB occurred most frequently (67.9%) followed by SgC (25.0%), SgY 
(3.4%) and SgW135 (2.2%). SgB was most common among IMD cases in infants (80.1%) and least 
common in children aged 5–14 years (60.9%). The proportion of cases with SgC was highest in 
children aged 5–14 years (32.8%) and lowest in infants (16.7%). The proportion of cases presenting 
with SgY and SgW135 was highest in adults>50 years (10.8% and 6.2%, respectively). There was a 
significant decrease in the proportion of SgC IMD from 2006 to 2010 overall (29.3%–21.9%,  
ptrend = 0.02) and in 6–14 year-old children (35.8%–15.8%, ptrend = 0.02). The decrease in the 
proportion of SgC IMD in 1–5 year olds (27.4%–20.0%, ptrend = 0.09) and 15–24 year olds (31.3%–
21.3%, ptrend = 0.08) did not reach significance, and there was no change in adults and infants. 
The distribution of serogroups according to age (Figure 1) is relevant for assessment of potential 
vaccination impact. Thus, 17.1% of all SgB cases and 9.8% of SgC cases occurred in infants (which 
comprise 0.8% of the German population). The highest proportion of SgB and SgC cases occurred in 
0–4 and 15–19 year-olds, and the highest proportion of SgY and W135 cases in adults ≥50 years 
(Figure 1). 
The decrease in total IMD incidence was reflected in significantly declining trends for SgB and SgC 
(Figure 2A). SgY incidence showed an increasing trend that was significant only in adults ≥50 years 
(Figure 2B). Both SgC and SgB incidence decreased significantly in persons aged 0, 1–5, 6–14, and 
15–24 years, but not in adults (Figure 2C and D). The decreasing trend in SgC IMD was similar in 
magnitude before and after the SgC vaccination recommendation in 2006 in all age groups. However, 
the decreasing trend for SgC was significantly steeper than for SgB in 1–5 year old children, the major 
vaccination target group (p = 0.001), and overall (p = 0.009), with no difference in other age groups 
(Figure 2C and D). 
When stratifying SgC incidence according to vaccination coverage, the decreasing trend for SgC in 
persons aged 1–24 years (age group targeted for vaccination including individual catch-up since 2006) 
was steeper in states with higher (Incidence rate ratio (IRR) = 0.83, 95%CI: 0.80–0.86, p < 0.0001) 
than lower vaccination coverage (IRR = 0.89, 95%CI: 0.86–0.93, p < 0.0001; p for slope difference = 
0.01) (Figure 3). While this pattern was seen for all age groups within 1–24 years, differences in 
individual age groups were not statistically significant (online Table 2). In contrast, there were no 
differences in the decreasing trend for SgB IMD incidence according to vaccination coverage in 1–24 
year olds (IRR = 0.92, 95%CI: 0.89–0.95, p < 0.0001 and IRR = 0.93, 95%CI: 0.90–0.96, p < 0.0001, 
respectively) or any other age group (p > 0.23 in all groups). 
There was regional variation of IMD with on average higher total and SgB-incidence in Midwestern 
and Eastern states and highest SgC- and SgY-incidence in Midwestern and Southern states. These 
regional differences were statistically significant for SgB and SgY, but not for SgC incidence (Table 3). 
 
Finetype diversity in relation to serogroup-specific IMD incidence and SgC vaccination 
Since recommendation of SgC vaccination, only a modest decrease occurred in the two most common 
SgC finetypes C:P1.5,2:F3-3 and C:P1.5-1,10-8:F3-6 (Figure 4). While the age distribution of cases 
with the most common finetype C:P1.5,2:F3-3 was similar to the overall SgC age distribution, C:P1.5-
1,10-8:F3-6 occurred predominantly in young adults not targeted for vaccination, with only 25.0% of 
cases in children<15 years of age, compared to 51.1% overall. A disproportionate decrease was 
observed in the group of the 10 next most common SgC finetypes, which collectively made up a 
significant proportion of cases prior to introduction of SgC vaccination (Figure 4), from 49 cases in 
2002, to 32 in 2006, to 3 cases in 2010. For comparison, the number of cases with all other SgC 
finetypes decreased from 85 in 2002 to 83 in 2006 to 63 in 2010. This development was accompanied 
by a decrease in finetype diversity in SgC cases since 2006: From 2002 to 2005 the index of 
discrimination D fluctuated between 0.82 and 0.86, then decreased from 0.81 in 2006 to 0.69 in 2009, 
although increasing again to 0.76 in 2010 (Figure 5). The correlation between SgC incidence and 
finetype diversity from 2002 to 2010 was significant (Spearman's rho = −0.88, p = 0.002). No such 
decrease in diversity was observed in SgB finetypes despite the decreasing trend in SgB incidence, 
with D ranging from 0.93 to 0.97 during 2002–2010 (Figure 5), nor were incidence and diversity 
correlated (Spearman's rho = −0.25, p = 0.52). The increase in SgY incidence in >50 year-olds after 
2006 was not primarily due to an increase in the most common finetype Y:P1.5-2,10-1:F4-1 (10/11 
finetyped SgY cases in 2005–2006 but 20/37 cases in 2007–2010), but rather to an increase in 
several rarer SgY finetypes, as was the isolated increase in 15–24 year olds in 2009 (Figure 2B). This 
was reflected in increased SgY-associated finetype diversity in 2007–2010 (D = 0.64–0.83) compared 
to 2003–2006 (0.48–0.57, Figure 5), but correlation between incidence and diversity was not 
statistically significant (Spearman's rho = 0.30, p = 0.43). 
 
Discussion 
Surveillance of IMD in Germany is nationwide and comprehensive, with a high proportion of cases 
undergoing serogrouping and genetic typing. Thus detailed epidemiological analyses required for 
public health decisions are possible. Available data suggest that the degree of underascertainment 
has decreased: A capture-recapture study that compared isolates analysed at NRLM and the statutory 
surveillance system estimated an underascertainment of ∼11% in the statutory system in 2003,
13
 in 
keeping with the rather high proportion of NRLM cases that could not be matched to a notified case in 
2002 and 2003. This proportion decreased markedly after direct reporting of NRL results to LHA 
(rather than only to primary laboratories) was instituted in 2004 and has remained low at ∼3% since 
2006. However, an analysis of cases with either WHS or purpura fulminans notified to the LHA as 
suspected IMD, but not transmitted to the national level due to lack of laboratory confirmation, 
suggests additional underascertainment of 4–8%.
14
 
The distribution of serogroups in our dataset was similar to that described in other European 
countries,
1 and 15
 with a preponderance of SgB cases, followed by SgC and SgY cases. According to 
national IMD surveillance data submitted to the European Centre for Disease Control and Prevention 
(ECDC),
1
 the number of reported SgB IMD cases in 24 European countries decreased by ∼33% from 
2003 to 2009, comparable to observations in Germany (34%). An overall 52% decrease was observed 
in reported SgC IMD cases (51% in Germany) in these countries. A marked decrease in the proportion 
of SgC IMD from >30% to <5% was described collectively for the 10 countries with SgC vaccination 
programmes. 
In an analysis of data from 6 European countries that implemented routine conjugate SgC vaccination, 
the reported decline in SgC IMD incidence in the years following implementation (Belgium (2002), 
Iceland (2002), Ireland (2000), Netherlands (2002), Spain (2000) and the UK (1999)) was more rapid 
than seen in Germany.
16
 However, baseline SgC IMD incidence prior to the vaccination 
recommendation was much higher than in Germany (∼1–4.5 cases/100,000 inhabitants vs. 0.2–0.3 
cases/100,000 inhabitants), and all 6 performed catch-up vaccination campaigns in older children.
16
 
Herd effects were later demonstrated in the UK and the Netherlands.
17 and 18
 SgC incidence in these 
countries continues to be extremely low at 0.04 and 0.07, respectively.
1
 Modelling studies in England 
suggest that carriage reduction achieved by the catch-up campaign, particularly in adolescents, who 
have the highest carriage rates
19 and 20
 remains instrumental in maintaining low IMD incidence in the 
UK.
21
 This is supported by data reported to ECDC,
1
 according to which the proportion of SgC IMD 
among all serogrouped IMD cases in 2009 was 0% in Iceland, 0.5% in the UK, 5.1% in the 
Netherlands, 3.7% in Ireland, and 1.8% in Portugal, where catch-up campaigns targeted all persons 
up to 18 years or even older. In contrast, in Spain, where catch-up vaccination was limited to children 




 where catch up was limited to 1-6 year-olds in 
French regions and to 1–6 year olds and 15-18 year-olds in Flanders, the proportion of SgC IMD was 
higher at 7.1% and 13.8%, respectively, but still lower than in Germany (21.9%) or in countries that did 
not implement SgC vaccination before 2010, e.g. France (22.7%) or Denmark (32.8%).
1
 
The stronger decline in SgC than SgB IMD in children aged 1–5 years (i.e. the primary vaccination 
target group), the steeper decline of SgC cases in federal states with higher SgC vaccination 
coverage, and a significant decrease in the proportion of SgC IMD cases since 2006 suggest that 
vaccination is contributing to the decline in SgC IMD in Germany. However, interpretation is 
complicated by the already low and declining SgC incidence prior to implementation of routine SgC 
vaccination and the consequent low overall numbers of cases, limiting the power of our trend analyses 
before and after implementation of vaccination. Nonetheless, the impact of SgC vaccination appears 
limited compared to that seen in countries that implemented catch-up campaigns. 
While primary data on vaccination coverage were only available for children at school entry from 2008 
onwards for 13/16 federal states, nationwide data on the number of prescribed vaccines was helpful in 
supplementing these data for the purpose of categorizing states according to higher or lower levels of 
SgC vaccine uptake. Unpublished results of a mail survey of 7078 German households participating in 
a representative health panel performed in 2009 by the market research company GfK 
(http://www.gfk.de/) funded by Baxter and Novartis Vaccines showed regional variation similar to that 
observed with the data from school entry examinations and vaccine prescription data above. In this 
survey, vaccination coverage was highest in children aged 2–5 years (78.3%), followed by 6–10 year 
olds (58.6%), 0–1 year olds (36.3%), 11–16 year olds (36%), and 17–18 year olds (27.8%)(F. Weidle, 
GfK, personal communication). These rates are much lower than those achieved in countries such as 
the UK (≥93% by second birthday since 2005, and ≥85% among 5–17 year old children in the school-
based catch-up campaign
21
) or the Netherlands, in which coverage of 94% was achieved in 1–18 year 
old persons within the catch-up campaign.
17
 Thus, vaccination coverage attained through a 
recommendation for “individual”-based catch-up in Germany appears inadequate to achieve reduction 
of carriage in older children with the highest carriage rates,
24
 and thus to have a major impact on 
transmission. The relatively rapid loss of immunity after a single dose of SgC conjugate vaccine 
among children vaccinated at a young age
25
 may further undermine population immunity in Germany. 
The decrease in incidence of SgC, but not SgB IMD was associated with a decrease in finetype 
diversity. The interplay between carriage and disease of meningococci is complex,
26
 involving 
carriage-induced immunity over time as well as virulence factors of carried strains. We hypothesize 
that strains causing IMD more frequently are also more frequently carried and/or transmitted in the 
population, thus requiring higher vaccination coverage to interrupt their transmission. In contrast, 
strains causing disease more rarely are presumably also associated with lower carriage/transmission 
rates, such that lower vaccination coverage might be sufficient to reduce transmission. This hypothesis 
is supported by the disproportionate decrease in rarer SgC finetypes observed after achievement of 
only moderate SgC vaccination coverage in Germany. 
SgY IMD was uncommon, with the highest incidence in adolescents. However, the proportion of cases 
was highest in older adults, in whom incidence also increased significantly, albeit on a very low 
absolute level (Figure 2B). A recent increase in SgY incidence has been reported from several 
European countries,
1 and 27
 but this development does not seem to be a homogenous phenomenon. 
For instance, in Sweden, the increase was due mainly to an increase in finetype Y:P1.5-2,10-1:F4-1 in 
young adults,
27
 also the most common finetype in Germany. However, in Germany, the observed 
increase in SgY disease seen primarily in older adults was to a large extent due to cases with several 
different rarer SgY finetypes, as reflected in the increase in finetype diversity. In contrast, in England 
and Wales an increase in SgY IMD from 2007 to 2009 was associated primarily with finetype Y:P1.5-
1,10-1:F4-1. The current epidemiological situation in Germany does not justify a general 
recommendation for SgY conjugate vaccination. 
The high incidence of SgB disease in infants with a large proportion of cases in the first 6 months of 
life (59% of infant cases) should be considered when developing vaccination strategies for newly 
developed SgB vaccines
28
 expected shortly on the European market. The overall low incidence of SgB 
IMD in Germany demands careful evaluation of costs and benefits in the development of SgB 
vaccination recommendations. 
In conclusion, IMD incidence in Germany decreased to its lowest level in 2010 since initiation of 
mandatory surveillance. Our results suggest a very limited contribution of SgC vaccination to the 
decline in SgC IMD in Germany. The apparent stronger effect of only moderate vaccination coverage 
on IMD due to rarer versus more common SgC strains sheds light on the poorly understood 
transmission dynamics of IMD. Together with modelling studies based on effects seen in other 
countries with vaccination programmes, our results suggest that a more effective use of resources for 
SgC IMD vaccination could be achieved in Germany by specifically targeting adolescents in addition to 
1-year olds rather than recommending catch-up for all children up to age 17 on an individual basis. 
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Tables and Figures 
Table 1. Coverage with conjugate meningococcal C (SgC) vaccines at school entry 2009, and 
prescribed number of conjugate SgC vaccine doses per 1000 children 2006–2010, Germany 
 
SgC vaccination coverage 
at school entry 




2010 2006 2007 2008 2009 2010 Mean 2006–2010 
Bavaria No data 311 1028 2761 1859 1338 1460 
Hesse 59.9% 413 1019 2231 2427 1576 1533 
Thuringia 52.8% 812 982 851 3450 2064 1632 
Hamburg 65.7% 371 2308 2517 1857 1249 1660 
Saxony-Anhalt 72.3% 580 1266 1386 2652 2475 1672 
Rhineland-Palatinate No data 236 1851 3150 2014 1376 1725 
Bremen No data 75 2712 2359 1914 1568 1725 
Schleswig-Holstein 60.9% 351 3361 2453 1627 968 1752 
Baden-Württemberg 73.2% 608 4029 2353 1618 1211 1964 
Lower Saxony 59.8% 390 3096 2664 2205 1711 2013 
Berlin 77.7% 1480 4329 2430 1672 1277 2237 
Brandenburg 81.8% 671 4413 2966 1789 1424 2253 
Saarland 77.3% 1348 5007 2763 1797 1147 2412 
North Rhine-
Westphalia 
75.9% 310 5297 3191 1846 1427 2414 
Mecklenburg-Western 
Pomerania 
89.5% 2037 5777 2924 1738 1394 2774 
Saxony 84.4% 5970 3313 2374 1976 1743 3075 
Total 69.8% 756 3220 2644 1959 1454 2007 
a
 Rates > 1000 reflect catch-up vaccination of older children, recommended by STIKO on an  
individual basis. Shaded states were categorized as having lower and unshaded states as  
having higher vaccination uptake (see text). 
Table 2. Case fatality of invasive meningococcal disease according age and serogroup, Germany, 
2002–2010 (n = 441 deaths). 
Age (years) 
% Case fatality (95% CI) 
  
Serogroup C Serogroup B All serogroups 
0 9.9% (5.1–17.0%) 9.1% (6.8–11.8%) 9.3% (7.3–11.6%) 
1–4 11.6% (7.7–16.5%) 9.6% (7.5–12.0%) 9.0% (7.4–10.9%) 
5–14 5.7% (3.0–9.7%) 3.8% (2.2–6.2%) 4.2% (2.9–6.0%) 
15–24 11.6% (8.3–15.5%) 6.2% (4.7–8.1%) 7.2% (5.9–8.7%) 
25–49 15.2% (9.1–23.2%) 8.6% (5.6–12.5%) 10.1% (7.6–13.1%) 
50+ 22.8% (15.7–31.2%) 15.9% (11.8–20.7%) 15.8% (13.0–19.1%) 
Total 11.9% (10.0–13.9%) 8.3% (7.3–9.3%) 8.8% (8.0–9.6%) 
Table 3. Mean incidence of notified invasive meningococcal disease (cases/100,000 inhabitants) by 
serogroup and region, Germany, 2002–2010. 
Northwest Midwest South East p
a
 
Serogroup C 0.164 0.179 0.183 0.155 0.09 
Serogroup B 0.456 0.519 0.369 0.613 0.0002 
Serogroup Y 0.018 0.024 0.033 0.013 0.02 
Other Serogroups 0.049 0.032 0.034 0.019 0.09 
All serogroups 0.686 0.752 0.618 0.800 0.001 
 
Northwest: Lower Saxony, Bremen, Hamburg, Schleswig-Holstein; Midwest: Hesse, North Rhine-
Westphalia, Rhineland-Palatinate, Saarland; South: Bavaria, Baden-Württemberg; East: Mecklenburg 
Western Pomerania, Brandenburg, Berlin, Saxony Anhalt, Saxony, Thuringia. 
a
 Determined in negative binomial regression model. 
 
 
Figure 1. Age distribution of notified IMD cases according to serogroup, Germany, 2002–2010. 
Numbers in bars denote the total number of cases notified from 2002 to 2010. 
 
  
Figure 2.IMD incidence according to age and serogroup over time, 2002–2010. A: Total IMD 
incidence for SgB (Incidence rate ratio (IRR) = 0.93; 95%CI: 0.91–0.95, p < 0.0001), SgC (IRR = 0.89; 
95%CI: 0.86–0.91, p < 0.0001) and SgY (IRR = 1.06; 95%CI: 1.00–1.12, p = 0.05). B: Age-specific 
SgY incidence: IRR significant only in persons ≥50 years (IRR = 1.18; 95%CI: 1.07–1.30, p = 0.003). 
C: Age-specific SgC incidence: Significant decrease in persons aged 0 (IRR = 0.90; 95%CI: 0.83–
0.97, p = 0.007) 1–5 (IRR = 0.81; 95%CI: 0.77–0.86, p < 0.0001), 6–14 (IRR = 0.84; 95%CI: 0.78–
0.90, p < 0.0001) and 15–24 years (IRR: 0.91; 95%CI: 0.87–0.95, p < 0.0001), but not adults ≥25 
years (IRR = 1.00; 95CI: 0.95–1.04, p = 0.88). D: Age-specific SgB incidence: significant decrease in 
persons aged 0 (0.94; 95%CI: 0.90–0.98, p = 0.006), 1–5 (IRR = 0.92; 95%CI: 0.88–0.95, p < 0.0001), 
6–14 (IRR = 0.91; 95%CI: 0.86–0.96, p < 0.0001), 15–24 years (IRR = 0.95; 95%CI: 0.92–0.97,  
p < 0.0001), but not in adults ≥25 years (IRR = 0.98; 95%CI: 0.95–1.00, p = 0.10). 
 
  
Figure 3. Incidence of IMD due to SgC in persons aged 1–24 years, 2002–2010, in states with lower 




Figure 4. IMD cases due to serogroup C according to finetype by year, Germany, 2002–1010. 
 
 
Figure 5. Index of discrimination for finetypes according to serogroups B, C and Y, Germany, 2002–
2010. Note: Scale of Y axes differs. 
 
